Difference between revisions of "Team:CGU Taiwan/Description"

 
(116 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
<html>
 
<html>
 
<meta http-equiv="X-UA-Compatible" content="IE=edge">
 
<meta http-equiv="X-UA-Compatible" content="IE=edge">
−
<meta name="viewport" content="width=device-width, initial-scale=1.0">
 
 
<style>
 
<style>
 
         #sideMenu
 
         #sideMenu
Line 15: Line 14:
 
#content { padding:0px; width:100%; margin-left:0%; margin-right:0%;}
 
#content { padding:0px; width:100%; margin-left:0%; margin-right:0%;}
 
</style>
 
</style>
−
 
−
<head>
 
−
<meta charset="utf-8">
 
−
<meta http-equiv="X-UA-Compatible" content="IE=edge">
 
−
<meta name="viewport" content="width=device-width, initial-scale=1">
 
−
</head>
 
 
<!-- ////////////////////// START  TOP HEADER /////////////////////// -->
 
<!-- ////////////////////// START  TOP HEADER /////////////////////// -->
 
<head>
 
<head>
Line 29: Line 22:
 
.top {
 
.top {
 
   position: absolute;
 
   position: absolute;
−
   top: -10px;
+
   top: -1%;
−
   left: 0px;
+
   left: 0%;
−
  background:  #140731;
+
 
   width: 100%;
 
   width: 100%;
−
   height: 110px;
+
  box-sizing:border-box;
 +
   height: 115px;
 
   font-family: Corbel;
 
   font-family: Corbel;
−
   overflow: visible;
+
   overflow:visible;
 +
  z-index: +1;
 
}
 
}
 
.mid {
 
.mid {
 
   position: absolute;
 
   position: absolute;
−
   left: 0px;
+
   left: 5%;
−
   width: 100%;
+
   width: 80%;
 
   height: 100%;
 
   height: 100%;
 
   font-family: Corbel;
 
   font-family: Corbel;
−
  z-index:-1;
 
 
}  
 
}  
 
.headline {
 
.headline {
Line 52: Line 45:
 
}
 
}
 
.header-subnav  {
 
.header-subnav  {
−
   background: #140731;
+
   background: #0D014D;
 
   width: 100%;
 
   width: 100%;
 
   position: absolute;
 
   position: absolute;
 
   text-align: center;
 
   text-align: center;
 
   margin: 0 auto;
 
   margin: 0 auto;
−
   top: 100px;
+
   top: 117%;
−
  left:-20px;
+
  left: 0%;
 
   font-family: Corbel;
 
   font-family: Corbel;
 +
  z-index:-1;
 
}
 
}
 
.header-subnav li {
 
.header-subnav li {
Line 91: Line 85:
 
.circle {
 
.circle {
 
   position:absolute;
 
   position:absolute;
−
   left: 1160px;
+
   left: 85.5%;
−
   top: 30px;
+
   top: 70%;
 
   width: 180px;
 
   width: 180px;
 
   height: 180px;
 
   height: 180px;
−
   background: #140731;
+
   background: #0D014D;
 
   -moz-border-radius: 90px;
 
   -moz-border-radius: 90px;
 
   -webkit-border-radius: 90px;
 
   -webkit-border-radius: 90px;
Line 101: Line 95:
 
}
 
}
 
.left {
 
.left {
−
   position: fixed;
+
  padding: 10px;
−
   left: 0px;
+
  height:200px;
−
   top: 175px;
+
  border-color:#140731;
 +
  border-radius:8px;
 +
  border-width:2px;
 +
  border-style:solid;
 +
   position: absolute;
 +
   left: 25px;
 +
   top: 230px;
 
   font-family: Corbel;
 
   font-family: Corbel;
 
   background: rgba(250, 250, 250, 0.15);
 
   background: rgba(250, 250, 250, 0.15);
−
   width: 150px;
+
   width: 170px;
 
   z-index:+1;
 
   z-index:+1;
 
}
 
}
 +
 
.left-tab {
 
.left-tab {
 
   background-color: rgba(250, 250, 250, 0.1);
 
   background-color: rgba(250, 250, 250, 0.1);
Line 132: Line 133:
 
   border-radius: 4px;
 
   border-radius: 4px;
 
}
 
}
 +
.fixed2 {
 +
  position: fixed;
 +
  top: 68px;
 +
}
 +
 
.button {
 
.button {
 
   background-color: rgba(250, 250, 250, 0.1);
 
   background-color: rgba(250, 250, 250, 0.1);
Line 252: Line 258:
 
   background-color: #FF8800;
 
   background-color: #FF8800;
 
   height: 2px;
 
   height: 2px;
 +
}
 +
.list li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/b/ba/CGU_Taiwan--point.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:-10 5px;
 +
  padding-left:3%;
 +
  background-size:2.5%;
 +
}
 +
 +
.end2 {
 +
  background-color:#0D014D;
 +
  position: absolute;
 +
  width: 100%;
 +
  height: 215%;
 +
  font-family: Corbel;
 +
  z-index:+1;
 +
}
 +
.sitemap {
 +
  background-color:#0D014D;
 +
  position: absolute;
 +
  width: 20%;
 +
  height: 40%;
 +
  font-family: Corbel;
 +
}
 +
.list1 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/5/58/CGU_Taiwan--sitemap.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:10px;
 +
  background-size:9%;
 +
    margin-bottom:-20%;
 +
}
 +
.list2 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/2/2f/CGU_Taiwan--sitemap2.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:6px;
 +
  background-size:7%;
 +
  margin-bottom:-10%;
 +
}
 +
.list3 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:5%;
 +
  background-size:2%;
 +
  margin-bottom:-10%;
 
}
 
}
 
</style>
 
</style>
Line 268: Line 322:
 
     }
 
     }
 
});
 
});
 +
var num = 132; //number of pixels before modifying styles
 +
$(window).bind('scroll', function () {
 +
    if ($(window).scrollTop() > num) {
 +
        $('.left').addClass('fixed2');
 +
    } else {
 +
        $('.left').removeClass('fixed2');
 +
    }
 +
});
 +
  
  
 
//USE SCROLL WHEEL FOR THIS FIDDLE DEMO
 
//USE SCROLL WHEEL FOR THIS FIDDLE DEMO
 +
 +
 
</script>
 
</script>
 +
<script>
 +
var slideIndex = 1;
 +
showDivs(slideIndex);
  
 +
function plusDivs(n) {
 +
  showDivs(slideIndex += n);
 +
}
 +
 +
function currentDiv(n) {
 +
  showDivs(slideIndex = n);
 +
}
 +
 +
function showDivs(n) {
 +
  var i;
 +
  var x = document.getElementsByClassName("mySlides");
 +
  var dots = document.getElementsByClassName("demo");
 +
  if (n > x.length) {slideIndex = 1}
 +
  if (n < 1) {slideIndex = x.length}
 +
  for (i = 0; i < x.length; i++) {
 +
    x[i].style.display = "none";
 +
  }
 +
  for (i = 0; i < dots.length; i++) {
 +
    dots[i].className = dots[i].className.replace(" w3-border-red", "");
 +
  }
 +
  x[slideIndex-1].style.display = "block";
 +
  dots[slideIndex-1].className += " w3-border-red";
 +
}
 +
</script>
  
 
<body>
 
<body>
 +
<a name='anchor1'></a>
 
<div class="top">
 
<div class="top">
−
<a name='anchor0'></a>
+
<img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg">
−
<img alt="" style="position:absolute;z-index:++1;float:left;margin-top:20px;width:390px;height:80px;"  src="https://static.igem.org/mediawiki/2016/b/bb/CGU_Taiwan--logo2.jpg">
+
</div>
−
<img style="position:absolute;left:1170px;top:35px;z-index:+1;width:155px;height:180px;" src="https://static.igem.org/mediawiki/2016/8/8a/CGU_Taiwan--logo9.jpg">
+
−
<div class="circle"></div>
+
 
</div>
 
</div>
  
 
<header class="top">
 
<header class="top">
−
<h1 class="headline">Leijuvant</h1>
 
 
<ul class="header-subnav">
 
<ul class="header-subnav">
 
<li><a href="https://2016.igem.org/Team:CGU_Taiwan">HOME</a></li>
 
<li><a href="https://2016.igem.org/Team:CGU_Taiwan">HOME</a></li>
Line 295: Line 385:
 
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts">PARTS</a></li>
 
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts">PARTS</a></li>
 
</ul>
 
</ul>
 +
<div class="circle"><img style="position:absolute;z-index:+1;width:90%;height:95%;margin-left:3%;margin-top:2%;" src="https://static.igem.org/mediawiki/2016/8/8a/CGU_Taiwan--logo9.jpg"></div>
 
</header>
 
</header>
  
−
<div class="left" style="height:800px;">
+
<div class="left">
−
<a href="#anchor0"><section class="left-tab" style="position:fixed;top:185px;left:20px;" id="myP" onmousedown="mouseDown()" onmouseup="mouseUp()">TOP</section>
+
<a href="#anchor1"><section class="left-tab" style="top:240px;" id="myP" onmousedown="mouseDown()" onmouseup="mouseUp()"><b>TOP</b></section></a>
−
<hr1 style="width:145px;position:absolute;left:15px;top:43px;"></hr1>
+
<a href="#anchor1"><section class="left-tab" style="top:275px;left:50px;">Overview</section></a>
 +
<a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style="top:310px;left:50px;">Design</section></a>
 +
<a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style="top:345px;left:50px;">Background</section></a>
 +
<a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><section class="left-tab" style="top:380px;left:50px;">Results</section></a>
 +
<a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><section class="left-tab" style="top:415px;left:50px;">Proof</section></a>
 +
<a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><section class="left-tab" style="top:450px;left:50px;">Notebook</section></a>
 +
</div>
  
−
<a href="#anchor1"><section class="left-tab" style="position:fixed;top:220px;left:10px;"><li>Overview</li></section>
+
<br><br><br>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style="position:fixed;top:255px;left:10px;"><li>Design</li></section>
+
<div class="mid">
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style="position:fixed;top:290px;left:10px;"><li>Background</li></section>
+
<div style="font-size:60px;color:#FF8800;text-decoration:none;margin-left:22%;margin-top:20%;">
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><section class="left-tab" style="position:fixed;top:325px;left:10px;"><li>Results</li></section>
+
Overview
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><section class="left-tab" style="position:fixed;top:365px;left:10px;"><li>Proof concept</li></section>
+
</div>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><section class="left-tab" style="position:fixed;top:400px;left:10px;"><li>Notebook</li></section>
+
<br><br><br>
 +
<img src="https://static.igem.org/mediawiki/2016/d/d2/CGU_Taiwan--overview-2.jpg" style="float:right;width:45%;height:150%;margin:20px;">
 +
<div style="color:black;font-size:18px;margin-left:22%;margin-right:5%;text-align:justify;text-decoration:none;">
 +
<b>Vaccines</b> save millions of lives each year and are among the greatest achievements of biomedical science and most cost-effective health interventions ever developed. Vaccines for diphtheria, mumps, pertussis, and tetanus are good examples. Recommendation of these vaccines before 1980 contributed to a greater than 92% decline in cases and a 99% or greater decline in deaths. Endemic transmission of poliovirus, measles, and rubella viruses has been eliminated in the United States; smallpox has been eradicated worldwide. Vaccine plays a very important role in disease control and elimination. By improving vaccines, many more lives could be saved each year.<sup>[1]</sup>
 +
</div>
 +
<br><br>
 +
<img src="https://static.igem.org/mediawiki/2016/f/f0/CGU_Taiwan--overview1.jpg" style="float:left;width:34%;height:180%;margin-left:22%;margin-right:8%;">
 +
<div style="color:black;font-size:18px;margin-left:22%;margin-right:5%;text-align:justify;text-decoration:none;">
 +
There are still a number of severe diseases that don't have an effective vaccine, such as hepatitis c, tuberculosis, and malaria. Researchers conclude that the reason why most of the vaccines against these diseases failed to stimulate effective immunity is due to the lack of T cell immune response. For many infectious diseases, <b>T cells</b> play an important role in naturally acquired protective immune response. T cells have to be activated to trigger humoral and cytotoxic pathways and they are essential to the induction of high-affinity antibodies and immune memory. Optimizing T cell response by vaccination has been the aim of many scientists and is thought to be the future of vaccine development.<sup>[2],[3]</sup>
 +
<br><br>
 +
To make a breakthrough of the dilemma, we focus on the enhancement of vaccines. Some of the vaccines are used along with immunologic <b>adjuvant</b> to stimulate an effective immune response. Adjuvants are compounds that can be added to vaccines to improve immunogenicity by triggering the innate immune responses and thus accelerate, prolong, or enhance antigen-specific immune response. However, the adjuvants nowadays are deficient in activation of T cell response. This year, we established a new model system to generate antigen-specific Leishmania adjuvant as a T cell stimulator - Leijuvant.
 +
<br><br><br><br>
 +
<div style="font-size:12px;">
 +
References:<br>
 +
1. Roush, S.W., T.V. Murphy, and a. Vaccine-Preventable Disease Table Working Group, HIstorical comparisons of morbidity and mortality for vaccine-preventable diseases in the united states. JAMA, 2007. 298(18): p. 2155-2163.<br>
 +
2. Gilbert, S.C., T-cell-inducing vaccines – what's the future. Immunology, 2012. 135(1): p. 19-26.<br>
 +
3. Ahlers, J.D. and I.M. Belyakov, Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood, 2010. 115(9): p. 1678.<br>
 
</div>
 
</div>
  
 +
</div>
  
  
−
<a name='anchor1'></a>
+
<br><br><br><br><br><br><br><br><br>
−
<div class="mid" style="top:155px;background-color:white;">
+
</div>
−
<br><br><br>
+
−
<h1 style="font-size:30px;color:#FF8800;text-decoration:none;position:absolute;left:180px;top:50px;margin:20px;">Overview</h1>
+
−
<hr style="width:780px;position:absolute;left:350px;top:92px;"></hr>
+
−
<a name='anchor3'></a>
+
−
+
−
<div style="position:absolute;width:900px;height:1500px;top:150px;left:250px;">  
+
  
−
 
−
  <img src="https://static.igem.org/mediawiki/2016/d/d2/CGU_Taiwan--overview-2.jpg" style="float:right;width:430px;height:320px;margin:20px;">
 
−
<p style="font-size:16px;">Vaccines save millions of lives each year and are among the greatest achievements of biomedical science and most cost-effective health interventions ever developed. Vaccines for diphtheria, mumps, pertussis, and tetanus are good examples. Recommendation of these vaccines before 1980 contributed to a greater than 92% decline in cases and a 99% or greater decline in deaths. Endemic transmission of poliovirus, measles, and rubella viruses has been eliminated in the United States; smallpox has been eradicated worldwide. Vaccine plays a very important role in disease control and elimination. By improving vaccines, many more lives could be saved each year.</p><br><br><br><br><br>
 
  
−
<img src="https://static.igem.org/mediawiki/2016/f/f0/CGU_Taiwan--overview1.jpg" style="float:left;width:350px;height:300px;margin:20px;">
 
  
−
<p style="font-size:16px;">There are still a number of severe diseases that don't have an effective vaccine, such as hepatitis c, tuberculosis, and malaria. Researchers conclude that the reason why most of the vaccines against these diseases failed to sitmulate effective immunity is due to the lack of T cell immune response. For many infectious diseases, T cells play an important role in naturally acquired protective immune response. T cells have to be activated to trigger humoral and cytotoxic pathways and they are essential to the induction of high-affinity antibodies and immune memory. Optimizing T cell response by vaccination has been the aim of many scientists and is thought to be the future of vaccine development.</p><br><br><br><br>
+
 
−
 
+
<div class="end2" style="margin-top:130%;">
−
<p style="font-size:16px;">To make a breakthrough of the dilemma, we focus on the enhancement of vaccines. Some of the vaccines are used along with immunologic adjuvant to stimulate an effective immune response. Adjuvants are compounds that can be added to vaccines to improve immunogenicity by triggering the innate immune responses and thus accelerate, prolong, or enhance antigen-specific immune response. However, the adjuvants nowadays are deficient in activation of T cell response. This year, we established a new model system to generate antigen-specific Leishmania adjuvant as a T cell stimulator- Leijuvant.</p>
+
<br>
−
<br><br><br><br>
+
<ul class="list3" class="margin-left:1%;margin-top:2%;">
−
</div>
+
<li><a href="#anchor1"><b style="color:white;font-size:28px;margin-left:7%;">TOP</a></li>
 +
</ul>
 +
<br>
 +
<div class="sitemap" style="margin-left:5%;">
 +
<br>
 +
<b style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br>
 +
<br><br>
 +
<img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:40%;height:70%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg">
 
</div>
 
</div>
 +
<br>
  
 +
<div class="sitemap" style="margin-left:22%;margin-top:-1%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li></a>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:40%;margin-top:-2%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li></a>
 +
<br><br>
 +
</ul>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:55%;margin-top:-3.5%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li></a>
 +
</ul>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:75%;margin-top:-3.5%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;">
 +
<li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li></a>
 +
</ul>
 +
</ul>
 +
<ul class="list1" class="margin-left:1%;margin-top:-10%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:-5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><b style="color:white;font-size:17px;margin-left:10%;">Sponsors</li></a>
 +
</ul>
 +
</ul>
 +
</div>
 +
</div>
  
 
</body>
 
</body>
 
</html>
 
</html>

Latest revision as of 07:22, 2 December 2016

TOP
Overview
Design
Background
Results
Proof
Notebook



Overview



Vaccines save millions of lives each year and are among the greatest achievements of biomedical science and most cost-effective health interventions ever developed. Vaccines for diphtheria, mumps, pertussis, and tetanus are good examples. Recommendation of these vaccines before 1980 contributed to a greater than 92% decline in cases and a 99% or greater decline in deaths. Endemic transmission of poliovirus, measles, and rubella viruses has been eliminated in the United States; smallpox has been eradicated worldwide. Vaccine plays a very important role in disease control and elimination. By improving vaccines, many more lives could be saved each year.[1]


There are still a number of severe diseases that don't have an effective vaccine, such as hepatitis c, tuberculosis, and malaria. Researchers conclude that the reason why most of the vaccines against these diseases failed to stimulate effective immunity is due to the lack of T cell immune response. For many infectious diseases, T cells play an important role in naturally acquired protective immune response. T cells have to be activated to trigger humoral and cytotoxic pathways and they are essential to the induction of high-affinity antibodies and immune memory. Optimizing T cell response by vaccination has been the aim of many scientists and is thought to be the future of vaccine development.[2],[3]

To make a breakthrough of the dilemma, we focus on the enhancement of vaccines. Some of the vaccines are used along with immunologic adjuvant to stimulate an effective immune response. Adjuvants are compounds that can be added to vaccines to improve immunogenicity by triggering the innate immune responses and thus accelerate, prolong, or enhance antigen-specific immune response. However, the adjuvants nowadays are deficient in activation of T cell response. This year, we established a new model system to generate antigen-specific Leishmania adjuvant as a T cell stimulator - Leijuvant.



References:
1. Roush, S.W., T.V. Murphy, and a. Vaccine-Preventable Disease Table Working Group, HIstorical comparisons of morbidity and mortality for vaccine-preventable diseases in the united states. JAMA, 2007. 298(18): p. 2155-2163.
2. Gilbert, S.C., T-cell-inducing vaccines – what's the future. Immunology, 2012. 135(1): p. 19-26.
3. Ahlers, J.D. and I.M. Belyakov, Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood, 2010. 115(9): p. 1678.












SITE MAP